NCT00628680 - A Multi-Centered, Two-Arm, Randomized Study Comparing the Effects of AAT-023 (Zuragen) Solution, and Heparin on the Incidence of Catheter Related Blood Stream Infections in Tunneled Chronic Central Venous Catheters for Dialysis | Biotech Hunter

Enrollment

415

Participants

Timeline

Start Date

July 31, 2006

Primary Completion Date

July 31, 2008

Conditions

End Stage Renal Disease

Interventions

DEVICE

AAT-023 solution (Zuragen)

Amount equal to the catheter lumen plus 0.3mL. Three times per week (after each Hemodialysis) for 26 weeks

DRUG

Heparin

Hepaarin 5000 units diluted with normal saline to the exact catheter lumen volume.

Trial Locations (22)

14225

Hypertension & Renal Research Group, Buffalo

16507

Bayview Nephrology, Inc., Erie

21208

MId Atlantic Nephrology Associates, PA, Baltimore

30901

Nephrology Associates, P.C., Augusta

32806

Nephrology consultants, Orlando

33511

Brandon nephrology, Brandon

33778

Bay Breeze Dialysis, Largo

34471

Discovery Medical Research Group, Ocala

34608

Hernando Kidney Center, Spring Hill

34667

Bayonet Point Hudson Kidney Center, Hudson

Outcomes Research International, Inc., Hudson

34668

New Port Richey Kidney Center, New Port Richey

34698

Gulf Breeze Dialysis Center, Dunedin

48202

Henry Ford Hospital, Detroit

54911

Fox Valley Nephrology Associates, Appelton

77030

Kidney Associates, PLLC, Houston

77099

Southwest Houston Research, LTD, Houston

90262

Renal Medical Associates, Lynwood

93309

Bakersfield Dialysis Center, Bakersfield

06762

Nephrology & Hypertension Associates, PC, Middlebury

02135

Caritas St. Elizabeth Center, Boston

01107

Western New England Renal & Transplant Associatea, Springfield